尊敬的各位报告嘉宾、参会代表： 您好！ 2025（第四届）高分子3D打印材料高峰论坛 将于7月18-20日在 杭州龙禧福朋喜来登 举行 （18 日下午会议签到；19、20日主题报告） ，感谢您在百忙之中出席本次会议。为大家能够顺利地参与本 次会议，组委会准备了最全参会攻略，建议微信收藏，仔细阅读！ 论坛议程 （ 具体时间/顺序以会场现场为准 ） 开幕式 & 主论坛 增材制造的机遇与挑战 | 2025/07/19 (星期六 · 上午) | | | --- | --- | | 08:50-09:00 | 开幕式活动 | | 09:00-09:30 | 基于动态化学的可持续高性能光固化 3D 打印 谢涛,浙江大学教授 | | 09:30-10:00 | 连续纤维复合材料机器人激光增材制造技术 闫春泽,华中科技大学教授 | | 10:00-10:30 | 相变触发记忆还原: ActiveMemory ™智能材料在直接 3D 打印 正畸矫治器中的机制与应用 | | | 朱光,清锋科技有限公司联合创始人 & 首席技术官 | | 10:30-11:00 | 茶歇 & 展区参观 | | 11:00-11:30 | 生物 3D ...

Core Points - The annual general meeting of Shanghai Cathay Biotech Co., Ltd. is scheduled for June 27, 2025, at 14:00, combining on-site and online voting methods [3][4] - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching CNY 2,957.91 million, a 39.91% increase year-on-year, and net profit attributable to shareholders amounting to CNY 488.96 million, a 33.41% increase [16][32] - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, totaling CNY 287.58 million, based on the audited net profit for 2024 [8][9] Meeting Procedures - Attendees must register and confirm their attendance before the meeting starts, and they are required to present their shareholder certificates to enter the venue [2][3] - The meeting will include the election of monitors and counters, the presentation of the independent directors' report, and the discussion of various proposals [4][6][11] Financial Performance - The company achieved a net profit of CNY 488.96 million in 2024, with a significant increase in net profit excluding non-recurring gains and losses, which rose by 51.60% to CNY 464.73 million [16][32] - The total assets of the company reached CNY 19.02 billion, reflecting a stable financial position [32] Strategic Developments - The company has successfully introduced CNY 5.915 billion in funding through a directed issuance of shares to enhance its business development [18] - A strategic cooperation agreement was signed with Hefei Municipal Government and China Merchants Innovation Technology Group to establish a synthetic biological materials industry cluster [18][28] Governance and Compliance - The board of directors and the supervisory board have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations [19][25] - The company has maintained a high standard of information disclosure, achieving an A-level rating for its disclosure practices in the Shanghai Stock Exchange [23][26]

【SynBioCon】 获 悉，4月21日晚间， 凯赛生物 发布2024年年度报告。报告期内， 公司实现营业收入29.58 亿元，比上年同期上升39.91%，实 现营业利润 5.52 亿元，比上年同期上升21.41%；归属于上市公司股东的净利润 4.89 亿元，比上年同期上升33.41% 。 | | | | | 单位:元 币种:人民币 | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比上年 同期增减 | 2022年 | | | | | (%) | | | 营业收入 | 2, 957, 911, 554. 76 | 2, 114, 174, 868. 81 | 39. 91 | 2, 441, 103, 971. 54 | | 归属于上市公 司股东的净利 | 488, 961, 919. 11 | 366, 524, 351. 34 | 33. 41 | 553, 265, 973. 38 | | 润 | | | | | | 归属于上市公 司股东的扣除 | 464, 730, 541. 23 | 306, 551, 869. 92 | ...